- Home
- WYHG vs FBRX Comparison
WYHG vs FBRX Comparison
Compare WYHG & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- FBRX
- Stock Information
- Founded
- WYHG 1915
- FBRX N/A
- Country
- WYHG China
- FBRX United States
- Employees
- WYHG N/A
- FBRX N/A
- Industry
- WYHG
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- FBRX Health Care
- Exchange
- WYHG NYSE
- FBRX Nasdaq
- Market Cap
- WYHG 77.0M
- FBRX 84.0M
- IPO Year
- WYHG 2024
- FBRX N/A
- Fundamental
- Price
- WYHG $1.39
- FBRX $12.39
- Analyst Decision
- WYHG
- FBRX Strong Buy
- Analyst Count
- WYHG 0
- FBRX 2
- Target Price
- WYHG N/A
- FBRX $61.00
- AVG Volume (30 Days)
- WYHG 205.3K
- FBRX 167.7K
- Earning Date
- WYHG 08-15-2025
- FBRX 08-13-2025
- Dividend Yield
- WYHG N/A
- FBRX N/A
- EPS Growth
- WYHG N/A
- FBRX N/A
- EPS
- WYHG 0.20
- FBRX N/A
- Revenue
- WYHG $147,996,867.00
- FBRX N/A
- Revenue This Year
- WYHG N/A
- FBRX N/A
- Revenue Next Year
- WYHG N/A
- FBRX N/A
- P/E Ratio
- WYHG $4.49
- FBRX N/A
- Revenue Growth
- WYHG 19.02
- FBRX N/A
- 52 Week Low
- WYHG $1.10
- FBRX $4.11
- 52 Week High
- WYHG $12.00
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- FBRX 56.82
- Support Level
- WYHG N/A
- FBRX $10.15
- Resistance Level
- WYHG N/A
- FBRX $13.28
- Average True Range (ATR)
- WYHG 0.00
- FBRX 1.85
- MACD
- WYHG 0.00
- FBRX -0.16
- Stochastic Oscillator
- WYHG 0.00
- FBRX 30.06
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The main categories of products are cured meat products, including cured pork sausages, cured pork meat and other cured meat products, such as cured chicken, cured duck and cured fish; snack products, including ready-to-eat sausages, jerky, duck necks, duck feet and claypot rice; and frozen meat products, including frozen sausages, frozen beef patties and frozen chicken breast fillets.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).